Background: Psoriasis is a common, T-cell-mediated inflammatory and immune-mediated skin disease. Numerous studies confirmed that patients with psoriasis have a significant frequency of cardiovascular (CV) risk factors and CV diseases (CVDs). Risk stratification is helpful in light of the elevated risk of CVD in psoriasis patients. SCORE2 and SCORE2-OP, a new algorithm derived, calibrated and validated to predict the 10-year risk of first-onset CVD in European populations, enhances the identification of individuals at higher risk of developing CVD across Europe. Objective: Using the SCORE2 and SCORE2-OP scoring systems, the current study objective was to evaluate CV risk in Slovak psoriasis patients and the relationship between CV risk and psoriasis features in a real-world setting. Results: A case-control study was conducted involving 115 outpatients with plaque psoriasis and 66 age- and gender-matched controls with skin conditions other than psoriasis. Patients with psoriasis had significantly higher mean SCORE2 values. In the age group up to 50 years, more psoriasis patients were classified as moderate risk than controls (33.8% vs. 13.6%, p = 0.010); the high-risk category was dominated by psoriasis patients. Analysing the relationship between CV risk and selected variables, we determined, using linear regression, the dependence of the SCORE2 risk score on gender in the age group up to 50 years, on age in both age groups, on waist circumference (WC) in the category up to 50 years and on the duration and severity of psoriasis in both age groups using linear regression. For individuals older than 70, we estimated the SCORE2-OP risk score, with the average risk score being 19.5 ± 4.95. We did not observe controls with a high risk score. Psoriasis patients were more likely to be smokers and had significantly higher mean values for body mass index (BMI), WC, total cholesterol (TC), low-density lipoprotein (LDL) and systolic blood pressure (BP). Conclusions: Because CV risk factors and psoriasis are strongly related, the importance of CV risk stratification is growing, and initiating preventive lifestyle changes or therapeutic interventions in patients with psoriasis is warranted.

Department of Dermatovenerology Faculty of Medicine University Hospital P J Safarik University 040 01 Kosice Slovakia

Department of Health Psychology and Research Methodology Faculty of Medicine P J Safarik University 040 01 Kosice Slovakia

Department of Public Health and Hygiene Faculty of Medicine P J Safarik University 040 01 Kosice Slovakia

Olomouc University Social Health Institute Palacky University Olomouc 779 00 Olomouc Czech Republic

See more in PubMed

Boehncke W.H., Schön M.P. Psoriasis. Lancet. 2015;386:983–994. doi: 10.1016/S0140-6736(14)61909-7. PubMed DOI

Lockshin B., Balagula Y., Merola J.F. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J. Am. Acad. Dermatol. 2018;79:345–352. doi: 10.1016/j.jaad.2018.02.040. PubMed DOI

Boehncke W.H., Boehncke S., Tobin A.M., Kirby B. The ‘psoriatic march’: A concept of how severe psoriasis may drive car-diovascular comorbidity. Exp Dermatol. 2011;20:303–307. doi: 10.1111/j.1600-0625.2011.01261.x. PubMed DOI

SCORE2 Working Group. ESC Cardiovascular Risk Collaboration SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J. 2021;42:2439–2454. doi: 10.1093/eurheartj/ehab309. PubMed DOI PMC

Fernández-Torres R., Pita-Fernández S., Fonseca E. Psoriasis and cardiovascular risk. Assessment by different cardiovascular risk scores. J. Eur. Acad. Dermatol. Venereol. 2012;27:1566–1570. doi: 10.1111/j.1468-3083.2012.04618.x. PubMed DOI

Prodanovich S., Kirsner R.S., Kravetz J.D., Ma F., Martinez L., Federman D.G. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch. Dermatol. 2009;145:700–703. doi: 10.1001/archdermatol.2009.94. PubMed DOI

Cybulska B., Kłosiewicz-Latoszek L. Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years. Kardiologia Polska. 2019;77:173–180. doi: 10.5603/kp.a2019.0017. PubMed DOI

Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., et al. 2021 ESC Guidelines on cardiovascular disease pre-vention in clinical practice. G Ital Cardiol (Rome) 2022;23:e3–e115. PubMed

Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., Barengo N.C., Beaton A.Z., Benjamin E.J., Benziger C.P., et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010. PubMed DOI PMC

SCORE2-OP Working Group. ESC Cardiovascular Risk Collaboration SCORE2-OP risk prediction algorithms: Es-timating incident cardiovascular event risk in older persons in four geographical risk regions. Eur. Heart J. 2021;42:2455–2467. doi: 10.1093/eurheartj/ehab312. PubMed DOI PMC

Read S.H., van Diepen M., Colhoun H.M., Halbesma N., Lindsay R.S., McKnight J.A., McAllister D.A., Pearson E.R., Petrie J.R., Philip S., et al. Performance of cardiovascular disease risk scores in people diagnosed with type 2 diabetes: External validation using data from the national scottish diabetes register. Diabetes Care. 2018;41:2010–2018. doi: 10.2337/dc18-0578. PubMed DOI

Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS Guidelines for the managment of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455. PubMed DOI

Martinez-Moreno A., Ocampo-Candiani J., Garza-Rodriguez V. Psoriasis and Cardiovascular Disease: A Narrative Review. Korean J. Fam. Med. 2021;42:345–355. doi: 10.4082/kjfm.20.0053. PubMed DOI PMC

Eder L., Chandran V., Gladman D.D. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann. Rheum. Dis. 2013;73:1990–1996. doi: 10.1136/annrheumdis-2013-203433. PubMed DOI

Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corrà U., Cosyns B., Deaton C., et al. 2016 European Guidelines on cardiovascular disease pre-vention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur. Heart J. 2016;37:2315–2381. PubMed PMC

Gisondi P., Farina S., Giordano M.V., Girolomoni G. Usefulness of the Framingham risk store in patients with chronic psoriasis. Am. J. Cardiol. 2010;106:1754–1757. doi: 10.1016/j.amjcard.2010.08.016. PubMed DOI

Rosa D., Machado R., Matias F., Cedrim S., Noronha F., Gaburri D., Gamonal A. Influence of severity of the cutaneous manifestations and age on the prevalence of several cardiovascular risk factors in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2011;26:348–353. doi: 10.1111/j.1468-3083.2011.04076.x. PubMed DOI

Kimball A.B., Szapary P., Mrowietz U., Reich K., Langley R.G., You Y., Hsu M.-C., Yeilding N., Rader D.J., Mehta N.N. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J. Am. Acad. Dermatol. 2012;67:76–85. doi: 10.1016/j.jaad.2011.06.035. PubMed DOI

Gyldenløve M., Jensen P., Linneberg A., Thyssen J.P., Zachariae C., Hansen P.R., Skov L. Psoriasis and the Framingham risk score in a Danish hospital cohort. Int. J. Dermatol. 2013;53:1086–1090. doi: 10.1111/ijd.12196. PubMed DOI

Doukaki S., Caputo V., Bongiorno M.R. Psoriasis and Cardiovascular Risk: Assessment by CUORE Project Risk Score in Italian Patients. Dermatol. Res. Pr. 2013;2013:1–6. doi: 10.1155/2013/389031. PubMed DOI PMC

Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with pso-riasis. JAMA. 2006;296:1735–1741. doi: 10.1001/jama.296.14.1735. PubMed DOI

Armstrong A.W., Harskamp C.T., Armstrong E.J. The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies. Nutr. Diabetes. 2012;2:e54. doi: 10.1038/nutd.2012.26. PubMed DOI PMC

Gonzalez-Cantero A., Boehncke W.H., De Sutter J., Zamorano J.L., Lambert J., Puig L. Statins and psoriasis: Position statement by the Psoriasis Taks Force of the European Academy of Dermatology and Venerology. J. Eur. Acad. Dermatol. Venereol. 2023;37:1697–1705. doi: 10.1111/jdv.19191. PubMed DOI